Related Experiment Video

Updated: Aug 23, 2026

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)

Published on: April 7, 2021

Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome

M Hammoud1, N Al-Kazmi, M Alshemmiri

  • 1Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, Kuwait.

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|July 29, 2004
PubMed

Insights

Survanta demonstrated superior efficacy over Alveofact in treating respiratory distress syndrome (RDS) in preterm infants, leading to improved oxygenation and fewer chronic lung disease (CLD) complications.

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Natural surfactant preparations are vital for managing respiratory distress syndrome (RDS) in preterm infants.
  • Alveofact (SF-RI 1) and Survanta (barectant) are two natural surfactant options for RDS treatment.

Purpose of the Study:

  • To compare the efficacy of Alveofact and Survanta in reducing chronic lung disease (CLD) and other RDS complications.
  • To evaluate the impact of these surfactants on infant oxygenation and ventilation needs.

Main Methods:

  • Randomized controlled trial involving preterm infants with RDS requiring mechanical ventilation.
  • Infants received either Alveofact or Survanta, with outcomes including gas exchange, ventilatory settings, CLD incidence, and mortality assessed.

Main Results:

  • Survanta group showed improved oxygenation (lower FiO2) and earlier extubation.
  • Fewer infants in the Survanta group required postnatal steroids and experienced less CLD.
  • No significant differences were observed in ventilatory settings between the groups.

Conclusions:

  • Survanta offers greater benefits in improving oxygenation and reducing ventilatory support compared to Alveofact.
  • Survanta treatment was associated with a trend towards fewer serious pulmonary complications in preterm infants with RDS.
Abstract

More Related Videos

Intratracheal Instillation of Stem Cells in Term Neonatal Rats04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...